ROYCE MICRO-CAP TRUST, INC.

Form N-Q May 29, 2018 UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM N-Q

QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED

MANAGEMENT INVESTMENT COMPANY

Investment Company Act File Number: 811-08030

Name of Fund: Royce Micro-Cap Trust, Inc.

Fund Address: 745 Fifth Avenue

New York, NY 10151

Name and address of agent for service:

John E. Denneen, Esq.

Royce & Associates, LP

745 Fifth Avenue

New York, NY 10151

Registrant's telephone number, including area code: (212) 508-4500

Date of fiscal year end: 12/31/2018

Date of reporting period: 3/31/2018

Item 1 - Schedule of Investments

SCHEDULE OF INVESTMENTS ROYCE MICRO-CAP TRUST MARCH 31, 2018 (UNAUDITED)

	SHARES	VALUE
COMMON STOCKS 103.8%		
Consumer Discretionary Auto Components - 1.4% Fox Factory Holding 1 Motorcar Parts of America 1 Sebang Global Battery Standard Motor Products Stoneridge 1 Unique Fabricating	5,300 54,800 50,500 50,860 7,500 12,200	\$ 184,970 1,174,364 1,528,159 2,419,410 207,000 102,968
		5,616,871
Distributors - 0.6% Fenix Parts 1.2 Uni-Select Weyco Group	440,800 33,800 54,300	167,725 524,702 1,824,480
		2,516,907
Diversified Consumer Services - 1.8% American Public Education Aspen Group Collectors Universe Liberty Tax Cl. A Universal Technical Institute	54,798 141,520 108,200 142,900 270,000	2,356,314 999,131 1,699,822 1,443,290 793,800
		7,292,357
Hotels, Restaurants & Leisure - 1.4% Century Casinos 1 Del Taco Restaurants 1 Lindblad Expeditions Holdings 1 Lindblad Expeditions Holdings (Warrants) 1 Red Lion Hotels 1	222,500 8,200 254,000 18,100 115,500	1,659,850 84,952 2,608,580 27,150 1,126,125
		5,506,657
Household Durables - 3.0% AV Homes 1 Cavco Industries 1.3.4 Ethan Allen Interiors 3 Flexsteel Industries 3 Lifetime Brands 3 PICO Holdings 3.4 Skyline Corporation 1 Universal Electronics 1 ZAGG 1	82,000 20,241 18,100 16,100 119,294 142,000 63,700 6,100 121,600	1,521,100 3,516,874 415,395 637,238 1,479,245 1,625,900 1,401,400 317,505 1,483,520
Internet & Direct Marketing Retail - 0.7% FTD Companies 1	67,200	244,608

Gaia CI. A 1,3,4 Yatra Online 1	125,000 105,000	1,937,500 694,050
		2,876,158
Leisure Products - 0.7% Clarus Corporation Nautilus 1	174,926 118,500	1,180,751 1,593,825
		2,774,576
Media - 0.4% McClatchy Company (The) Cl. A <u>1</u> New Media Investment Group	69,313 66,200	641,145 1,134,668
		1,775,813
Multiline Retail - 0.0% Tuesday Morning 1,3	36,700	144,965
Specialty Retail - 1.3% AutoCanada Barnes & Noble Education ¹ Destination Maternity ¹ Destination XL Group ¹ Haverty Furniture Kirkland ﴿ MarineMax ¹ Sears Hometown and Outlet Stores ¹ Shoe Carnival ³ Stage Stores ³	115,200 80,000 212,000 50,000 30,000 11,000 7,600 269,700 21,028 15,000	1,988,627 551,200 549,080 87,500 604,500 106,590 147,820 809,100 500,467 32,700
		5,377,584
Textiles, Apparel & Luxury Goods - 1.1% Crown Crafts Culp J.G. Boswell Company ² YGM Trading	112,159 32,900 2,490 1,482,000	656,130 1,005,095 1,718,100 1,126,813 4,506,138
Total		50,786,203
Consumer Staples 2.6% Beverages - 0.2% Crimson Wine Group 1.2 Primo Water 1	58,124 40,400	574,265 473,084
F 10.01 1 P 17 0.40		1,047,349
Food & Staples Retailing - 0.1% Centric Health 1	807,600	288,350
Food Products - 2.2% AGT Food and Ingredients Farmer Bros. 1.3.4 John B. Sanfilippo & Son 3.4	25,800 62,600 17,800	334,227 1,890,520 1,030,086

Landec Corporation 1,3 Seneca Foods Cl. A 1 Seneca Foods Cl. B 1 SunOpta 1	75,610 81,087 40,400 176,281	986,711 2,246,110 1,125,140 1,251,595
		8,864,389
Household Products - 0.1% Central Garden & Pet 1	12,000	516,000
Total		10,716,088
Energy 7.0% Energy Equipment & Services - 3.4% Aspen Aerogels 1/2 CARRO Coronics 1.34	94,985	405,586
CARBO Ceramics 1.3.4 CES Energy Solutions Dawson Geophysical 1 Era Group 1 Geospace Technologies 1.3	70,000 25,000 73,654 329,800 9,500	507,500 114,100 496,428 3,083,630 93,765
Hornbeck Offshore Services 1,3,4 Independence Contract Drilling 1 Mammoth Energy Services 1 Matrix Service 1,3	460,000 134,400 9,900 33,700	1,338,600 508,032 317,394 461,690
Nabors Industries Newpark Resources North American Energy Partners Pioneer Energy Services Precision Drilling 1	34,000 11,200 50,000 245,600 108,600	237,660 90,720 265,000 663,120 300,822
SEACOR Marine Holdings 1 TerraVest Industries Total Energy Services Trican Well Service 1	205,457 109,000 25,700 53,300	3,907,792 835,891 274,285 124,112
		14,026,127
Oil, Gas & Consumable Fuels - 3.6%	100.000	4 544 000
Ardmore Shipping 1 Cross Timbers Royalty Trust Dorchester Minerals L.P. Dorian LPG 1 GeoPark 1 Hallador Energy Hugoton Royalty Trust Leucrotta Exploration 1 Pacific Ethanol 1 Panhandle Oil and Gas Cl. A Permian Basin Royalty Trust Sabine Royalty Trust San Juan Basin Royalty Trust StealthGas 1	199,300 67,631 153,963 148,138 61,971 24,000 287,574 489,800 134,300 5,500 176,333 59,548 143,407 229,664	1,514,680 987,413 2,478,804 1,109,554 768,440 164,880 201,302 615,885 402,900 106,150 1,701,613 2,617,135 1,132,915 920,953
		14,722,624
Total		28,748,751

Financials 14.8% Banks - 2.5%

Bank of N.T. Butterfield & Son Blue Hills Bancorp Bryn Mawr Bank Caribbean Investment Holdings Chemung Financial Fauquier Bankshares Live Oak Bancshares Midway Investments Peapack-Gladstone Financial	43,810 50,000 25,000 735,635 31,000 133,200 30,900 735,647 20,606	1,966,193 1,042,500 1,098,750 206,465 1,440,570 2,789,208 859,020 0 688,034
		10,090,740
Capital Markets - 9.4% ASA Gold and Precious Metals Ashford ¹ Banca Finnat Euramerica Canaccord Genuity Group Diamond Hill Investment Group ³ Donnelley Financial Solutions ¹ Dundee Corporation Cl. A ¹ EQT Holdings Fiera Capital Cl. A Founders Advantage Capital GAIN Capital Holdings ³ Gluskin Sheff + Associates GMP Capital Great Elm Capital Group ¹ Hamilton Lane Cl. A ³ INTL FCStone ¹.³.⁴ JZ Capital Partners ¹ Manning & Napier Cl. A Medley Management Cl. A MvC Capital OHA Investment Pzena Investment Management Cl. A Queen City Investments ² Silvercrest Asset Management Group Cl. A Sprott U.S. Global Investors Cl. A ³ Urbana Corporation Value Line Virtu Financial Cl. A ³ Warsaw Stock Exchange Westaim Corporation ¹ Westwood Holdings Group ³ ZAIS Group Holdings Cl. A ¹.³ ZAIS Group Holdings Cl. A ¹.³	171,150 5,600 568,000 203,300 3,584 50,000 413,200 4,926 78,000 53,400 25,000 67,400 332,800 425,200 32,300 63,727 209,999 136,600 153,400 341,430 59,761 6,100 948 203,300 1,414,533 439,454 237,600 136,074 107,800 52,900 45,000 12,400 262,960	1,783,383 535,976 313,592 1,093,545 740,311 858,500 593,333 81,743 665,363 89,114 168,750 762,752 715,532 1,700,800 1,202,529 2,719,868 1,399,446 478,100 874,380 3,390,400 83,666 67,893 1,118,640 3,090,160 3,414,598 1,111,819 610,437 2,490,154 3,557,400 639,004 98,847 700,476 1,064,988
		38,215,499
Consumer Finance - 0.7% Currency Exchange International 1 EZCORP CI. A 1.3.4	7,000 201,000	149,959 2,653,200 2,803,159
Diversified Financial Services - 0.1% Waterloo Investment Holdings 1,5	806,000	241,800
Insurance - 1.3% Atlas Financial Holdings 1	22,000	227,700

Investment Companies - 0.8% Social Capital Hedosophia Holdings \(\frac{1}{2} \) 340,168 3,411,885 340,168 3,411,885 340,168 3,411,885 340,168 3,411,885 340,168 3,411,885 340,168 3,411,885 340,168 3,411,885 340,168 3,411,885 340,168 3,411,885 340,168 3,411,885	Hallmark Financial Services 1,3,4 Heritage Insurance Holdings State Auto Financial Trupanion 1,3	114,000 6,600 59,264 82,300	1,016,880 100,056 1,693,172 2,459,947
Social Capital Hedosophia Holdings 340,168 3,411,885 Total			5,497,755
Health Care 13.7% Biotechnology - 4.8% Abeona Therapeutics ½ 142,221 2,040,871 Adplinox Pharmaceuticals ½ 145,397 2,047,190 ARCA biopharma ½ 326,147 162,878 Arcturus Therapeuticals ½ 106,436 585,398 BioCryst Pharmaceuticals ½ 144,000 686,880 CareDx ½ 56,000 446,320 Idera Pharmaceuticals ½ 156,412 733,572 Kindred Pharmaceuticals ½ 117,725 481,495 Kindred Biosciences ½ 126,000 1,089,900 Kinght Therapeutics ½ 187,000 1,124,889 Mirati Therapeutics ½ 61,100 1,875,770 Sangamo Therapeutics ½ 6,800 104,040 Theratechnologies ½ 10,000 72,418 Zafgen ½ 465,381 3,467,089 Zealand Pharma ½ 187,900 2,903,418 Zealand Pharma ½ 10,000 72,418 Zafgen ½ 465,381 3,467,089 Aricure ½ 18,000 307,800 Altricure ½³ </td <td></td> <td>340,168</td> <td>3,411,885</td>		340,168	3,411,885
Biotechnology - 4.8%	Total		60,260,838
Abeona Therapeutics 1.3 142,221 2,040,871 Aquinox Pharmaceuticals 1.3 145,397 2,047,190			
Aquinox Pharmaceuticals 1.3 145,397 2,047,190 ARCA biopharma 1 326,147 162,878 BioCryst Pharmaceutics 1 106,436 585,398 BioCryst Pharmaceuticals 1 144,000 686,880 CareDx 1 56,000 446,320 Idera Pharmaceuticals 1.3 156,412 733,572 Keryx Biopharmaceuticals 1.3 117,725 481,495 Kindred Biosciences 1 126,000 1,089,900 Kinght Therapeutics 1 187,000 1,124,889 Mirati Therapeutics 1 39,850 757,150 Stemline Therapeutics 1 39,850 757,150 Stemline Therapeutics 1 6,800 104,040 Theratechnologies 1 10,000 72,418 Zafgen 1 465,381 3,467,089 Zealand Pharma 2 10,000 150,200 Incomposition 18,200 1,745,380 Artiour 2.3 15,000 307,800 Altriour Corporation 6,169 3,894,490 Chembio Diagnostics 2 33,300 266,400		1/12/221	2 040 871
ARCA biopharma 1			
Arcturus Therapeutics ¹ 106,436 585,398 BioCryst Pharmaceuticals ¹ 144,000 686,880 CareDx ¹ 56,000 446,320 Idera Pharmaceuticals ¹ 464,490 854,662 Invitae Corporation ¹ 156,412 733,572 Keryx Biopharmaceuticals ¹¹² 117,725 481,495 Kindred Biosciences ¹ 126,000 1,089,900 Knight Therapeutics ¹ 61,100 1,875,770 Sangamo Therapeutics ¹ 39,850 757,150 Stemline Therapeutics ¹ 6,800 104,040 Theratechnologies ¹ 10,000 72,418 Zafgen ¹ 465,381 3,467,089 Zealand Pharma ¹ 187,900 2,903,415 Zealand Pharma ADR ¹ 10,000 150,200 Health Care Equipment & Supplies - 4.8% Analogic Corporation 18,200 1,745,380 AtriCure ¹.³ 15,000 307,800 Atrion Corporation 6,169 3,894,490 Chembio Diagnostics ¹ 33,300 266,400 CRH Medical ¹ 35,900 92,230 Inogen ¹ 5,400			
CareDx ¹ 56,000 446,320 Idera Pharmaceuticals ¹ 464,490 854,662 Invitae Corporation ¹ 156,412 733,572 Keryx Biopharmaceuticals ¹³ 117,725 481,495 Kindred Biosciences ¹ 126,000 1,089,900 Knight Therapeutics ¹ 187,000 1,124,889 Mirati Therapeutics ¹ 61,100 1,875,770 Sangamo Therapeutics ¹ 39,850 757,150 Stemline Therapeutics ¹ 6,800 104,040 Theratechnologies ¹ 10,000 72,418 Zafgen ¹ 465,381 3,467,089 Zealand Pharma ¹ 187,900 2,903,415 Zealand Pharma ADR ¹ 10,000 150,200 Inj,584,137 Health Care Equipment & Supplies - 4.8% Analogic Corporation 18,200 1,745,380 AtriOure ¹³ 15,000 307,800 AtriOure ¹³ 33,300 266,400 CRH Medical ¹ 133,000 336,539 CryoLife ¹ 4,600 92,230			
Idera Pharmaceuticals 1			
Invitae Corporation 156,412	—		
Keryx Biopharmaceuticals 1.3	-	•	
Kindred Biosciences 1 126,000 1,089,900 Knight Therapeutics 1 187,000 1,124,889 Mirati Therapeutics 1 61,100 1,875,770 Sangamo Therapeutics 1 39,850 757,150 Stemline Therapeutics 1 6,800 104,040 Theratechnologies 1 10,000 72,418 Zafgen 1 465,381 3,467,089 Zealand Pharma 1 187,900 2,903,415 Zealand Pharma ADR 1 10,000 150,200 Health Care Equipment & Supplies - 4.8% Analogic Corporation 18,200 1,745,380 AtriCure 1.3 15,000 307,800 Atrion Corporation 6,169 3,894,490 Chembio Diagnostics 1 33,300 266,400 CRH Medical 1 133,000 336,539 CryoLife 1 4,600 92,230 GenMark Diagnostics 1 35,900 195,296 Inogen 1 5,400 663,336 Invacare Corporation 3 54,100 941,340 Invairy 1 13,400 51,590<		,	
Mirati Therapeutics 1 61,100 1,875,770 Sangamo Therapeutics 1 39,850 757,150 Stemline Therapeutics 1 6,800 104,040 Theratechnologies 1 10,000 72,418 Zafgen 1 465,381 3,467,089 Zealand Pharma 1 187,900 2,903,415 Zealand Pharma ADR 1 10,000 150,200 Health Care Equipment & Supplies - 4.8% Analogic Corporation 18,200 1,745,380 AtriCure 1.3 15,000 307,800 Atricure 1.3 15,000 307,800 Atricure 1.3 33,300 266,400 CRH Medical 1 133,000 336,539 CryoLife 1 4,600 92,230 GenMark Diagnostics 1 35,900 195,296 Inogen 1 5,400 663,336 Invacare Corporation 3 54,100 941,340 Invuity 1 13,400 51,590 LeMaitre Vascular 5,000 181,150 OraSure Technologies 1.3 50,000 844,500			
Sangamo Therapeutics 1 39,850 757,150 Stemline Therapeutics 1 6,800 104,040 Theratechnologies 1 10,000 72,418 Zafgen 1 465,381 3,467,089 Zealand Pharma 1 187,900 2,903,415 Zealand Pharma ADR 1 10,000 150,200 Health Care Equipment & Supplies - 4.8% Analogic Corporation 18,200 1,745,380 AtrioCure 1.3 15,000 307,800 AtrioCorporation 6,169 3,894,490 Chembio Diagnostics 1 33,300 266,400 CRH Medical 1 133,000 336,539 CryoLife 1 4,600 92,230 GenMark Diagnostics 1 35,900 195,296 Inogen 1 5,400 663,336 Invacare Corporation 3 54,100 941,340 Invacare Corporation 3 54,100 941,340 Invalid Y 13,400 51,590 LeMaitre Vascular 5,000 181,150 OraSure Technologies 1.3 50,000 844,500 <			
Stemline Therapeutics 1 6,800 104,040 Theratechnologies 1 10,000 72,418 Zafgen 1 465,381 3,467,089 Zealand Pharma 1 187,900 2,903,415 Zealand Pharma ADR 1 10,000 150,200 Health Care Equipment & Supplies - 4.8% Analogic Corporation 18,200 1,745,380 AtriCure 1.3 15,000 307,800 Atrion Corporation 6,169 3,894,490 Chembio Diagnostics 1 33,300 266,400 CRH Medical 1 133,000 336,539 CryoLife 1 4,600 92,230 GenMark Diagnostics 1 35,900 195,296 Inogen 1 5,400 663,336 Invacare Corporation 3 54,100 941,340 Invuity 1 13,400 51,590 LeMaitre Vascular 50,000 844,500 OrthoPediatrics Corporation 1 33,300 501,498 STRATEC Biomedical 14,000 1,266,006 Surmodics 1 125,892 4,790,190 <td></td> <td></td> <td></td>			
Theratechnologies ½ 10,000 72,418 Zafgen ½ 465,381 3,467,089 Zealand Pharma ½ 187,900 2,903,415 Zealand Pharma ADR ½ 10,000 150,200 Health Care Equipment & Supplies - 4.8% Analogic Corporation 18,200 1,745,380 AtriCure ½³ 15,000 307,800 Atrion Corporation 6,169 3,894,490 Chembio Diagnostics ½ 33,300 266,400 CRH Medical ½ 133,000 336,539 CryoLife ½ 35,900 195,296 Inogen ½ 5,400 663,336 Invacare Corporation ¾ 54,100 941,340 Invuity ½ 13,400 51,590 LeMaitre Vascular 50,000 844,500 OraSure Technologies ½³ 50,000 844,500 OrthoPediatrics Corporation ½ 33,300 501,498 STRATEC Biomedical 14,000 1,266,006 Surmodics ½ 4,790,190 72,210			
Zafgen 1 465,381 3,467,089 Zealand Pharma 1 187,900 2,903,415 Zealand Pharma ADR 1 10,000 150,200 Health Care Equipment & Supplies - 4.8% Analogic Corporation 18,200 1,745,380 AtriCure 1.3 15,000 307,800 Atrion Corporation 6,169 3,894,490 Chembio Diagnostics 1 33,300 266,400 CRH Medical 1 133,000 336,539 CryoLife 1 4,600 92,230 GenMark Diagnostics 1 35,900 195,296 Inogen 1 5,400 663,336 Invacare Corporation 3 54,100 941,340 Invuity 1 13,400 51,590 LeMaitre Vascular 5,000 181,150 OraSure Technologies 1.3 50,000 844,500 OrthoPediatrics Corporation 1 33,300 501,498 STRATEC Biomedical 14,000 1,266,006 Surmodics 1 125,892 4,790,190 TearLab Corporation 1.2 8,500 2,210			
Zealand Pharma ADR ½ 150,200 Health Care Equipment & Supplies - 4.8% Analogic Corporation 18,200 1,745,380 AtriCure ½ 15,000 307,800 Atrion Corporation 6,169 3,894,490 Chembio Diagnostics ½ 33,300 266,400 CRH Medical ½ 133,000 336,539 CryoLife ½ 4,600 92,230 GenMark Diagnostics ½ 35,900 195,296 Inogen ½ 5,400 663,336 Invacare Corporation ½ 5,4100 941,340 Invuity ½ 13,400 51,590 LeMaitre Vascular 5,000 181,150 OraSure Technologies ½ 50,000 844,500 OrthoPediatrics Corporation ½ 33,300 501,498 STRATEC Biomedical 14,000 1,266,006 Surmodics ½ 125,892 4,790,190 TearLab Corporation ½ 8,500 2,210			
Health Care Equipment & Supplies - 4.8% Analogic Corporation 18,200 1,745,380 AtriCure 1.3 15,000 307,800 Atrion Corporation 6,169 3,894,490 Chembio Diagnostics 1 133,000 266,400 CRH Medical 1 133,000 336,539 CryoLife 1 4,600 92,230 GenMark Diagnostics 1 35,900 195,296 Inogen 1 5,400 663,336 Invacare Corporation 3 54,100 941,340 Invuity 1 13,400 51,590 LeMaitre Vascular 5,000 181,150 OraSure Technologies 1.3 50,000 844,500 OrthoPediatrics Corporation 1 33,300 501,498 STRATEC Biomedical 14,000 1,266,006 Surmodics 1 125,892 4,790,190 TearLab Corporation 1.2 8,500 2,210 10.000 1,2210 1.0000 1,2210 1.0000 1,2210 1.0000 1,2210 1.0000 1,2210 1.00000 1,2210 1.000000 1,2210 1.000000000000000000000000000000000		187,900	2,903,415
Health Care Equipment & Supplies - 4.8% Analogic Corporation 18,200 1,745,380 AtriCure 1,3 / 2 15,000 307,800 Atrion Corporation 6,169 3,894,490 Chembio Diagnostics 1 / 33,300 266,400 CRH Medical 1 / 133,000 336,539 CryoLife 1 / 4,600 92,230 GenMark Diagnostics 1 / 35,900 195,296 Inogen 1 / 5,400 663,336 Invacare Corporation 3 / 10,400 54,100 941,340 Invuity 1 / 1 / 13,400 51,590 LeMaitre Vascular 5,000 181,150 OraSure Technologies 1,3 / 2 50,000 844,500 OrthoPediatrics Corporation 1 / 2 33,300 501,498 STRATEC Biomedical 14,000 1,266,006 Surmodics 1 / 12,200 125,892 4,790,190 TearLab Corporation 1,2 / 2 8,500 2,210	Zealand Pharma ADR 1	10,000	150,200
Analogic Corporation 18,200 1,745,380 AtriCure 1,3 15,000 307,800 Atrion Corporation 6,169 3,894,490 Chembio Diagnostics 1 33,300 266,400 CRH Medical 1 133,000 336,539 CryoLife 1 4,600 92,230 GenMark Diagnostics 1 35,900 195,296 Inogen 1 5,400 663,336 Invacare Corporation 3 54,100 941,340 Invuity 1 13,400 51,590 LeMaitre Vascular 5,000 181,150 OraSure Technologies 1,3 50,000 844,500 OrthoPediatrics Corporation 1 33,300 501,498 STRATEC Biomedical 14,000 1,266,006 Surmodics 1 125,892 4,790,190 TearLab Corporation 1.2 8,500 2,210			19,584,137
AtriCure 1.3 / Atrion Corporation 15,000 / 307,800 Atrion Corporation 6,169 / 3,894,490 Chembio Diagnostics 1 / 33,000 / CRH Medical 1 / 133,000 / 336,539 33,300 / 336,539 CryoLife 1 / 4,600 / 92,230 4,600 / 92,230 GenMark Diagnostics 1 / 100gen	Health Care Equipment & Supplies - 4.8%		
Atrion Corporation 6,169 3,894,490 Chembio Diagnostics ½ 33,300 266,400 CRH Medical ½ 133,000 336,539 CryoLife ½ 4,600 92,230 GenMark Diagnostics ½ 35,900 195,296 Inogen ½ 5,400 663,336 Invacare Corporation ¾ 54,100 941,340 Invuity ½ 13,400 51,590 LeMaitre Vascular 5,000 181,150 OraSure Technologies ½ 50,000 844,500 OrthoPediatrics Corporation ½ 33,300 501,498 STRATEC Biomedical 14,000 1,266,006 Surmodics ½ 125,892 4,790,190 TearLab Corporation ½ 8,500 2,210			
Chembio Diagnostics 1 33,300 266,400 CRH Medical 1 133,000 336,539 CryoLife 1 4,600 92,230 GenMark Diagnostics 1 35,900 195,296 Inogen 1 5,400 663,336 Invacare Corporation 3 54,100 941,340 Invuity 1 13,400 51,590 LeMaitre Vascular 50,000 181,150 OraSure Technologies 1.3 50,000 844,500 OrthoPediatrics Corporation 1 33,300 501,498 STRATEC Biomedical 14,000 1,266,006 Surmodics 1 125,892 4,790,190 TearLab Corporation 1.2 8,500 2,210			
CRH Medical 1 133,000 336,539 CryoLife 1 4,600 92,230 GenMark Diagnostics 1 35,900 195,296 Inogen 1 5,400 663,336 Invacare Corporation 3 54,100 941,340 Invuity 1 13,400 51,590 LeMaitre Vascular 5,000 181,150 OraSure Technologies 1.3 50,000 844,500 OrthoPediatrics Corporation 1 33,300 501,498 STRATEC Biomedical 14,000 1,266,006 Surmodics 1 125,892 4,790,190 TearLab Corporation 1.2 8,500 2,210			
CryoLife ¹ 4,600 92,230 GenMark Diagnostics ¹ 35,900 195,296 Inogen ¹ 5,400 663,336 Invacare Corporation ³ 54,100 941,340 Invuity ¹ 13,400 51,590 LeMaitre Vascular 5,000 181,150 OraSure Technologies ¹.³ 50,000 844,500 OrthoPediatrics Corporation ¹ 33,300 501,498 STRATEC Biomedical 14,000 1,266,006 Surmodics ¹ 125,892 4,790,190 TearLab Corporation ¹.² 8,500 2,210	-		
Inogen 1 5,400 663,336 Invacare Corporation 3 54,100 941,340 Invuity 1 13,400 51,590 LeMaitre Vascular 5,000 181,150 OraSure Technologies 1.3 50,000 844,500 OrthoPediatrics Corporation 1 33,300 501,498 STRATEC Biomedical 14,000 1,266,006 Surmodics 1 125,892 4,790,190 TearLab Corporation 1.2 8,500 2,210			
Invacare Corporation 3 Invuity 1 Invuity Invu			
Invuity ½ 13,400 51,590 LeMaitre Vascular 5,000 181,150 OraSure Technologies ½ 50,000 844,500 OrthoPediatrics Corporation ½ 33,300 501,498 STRATEC Biomedical 14,000 1,266,006 Surmodics ½ 125,892 4,790,190 TearLab Corporation ½ 8,500 2,210			
LeMaitre Vascular 5,000 181,150 OraSure Technologies 1,3 50,000 844,500 OrthoPediatrics Corporation 1 33,300 501,498 STRATEC Biomedical 14,000 1,266,006 Surmodics 1 125,892 4,790,190 TearLab Corporation 1,2 8,500 2,210		,	
OraSure Technologies 1.3 / OrthoPediatrics Corporation 1 / STRATEC Biomedical 50,000 / S01,498 STRATEC Biomedical Surmodics 1 / TearLab Corporation 1.2 / TearLab Corporation 1.			
STRATEC Biomedical $14,000$ $1,266,006$ Surmodics $\frac{1}{2}$ $125,892$ $4,790,190$ TearLab Corporation $\frac{1.2}{2}$ $8,500$ $2,210$	OraSure Technologies 1,3	50,000	
Surmodics 1 125,892 4,790,190 TearLab Corporation 1.2 8,500 2,210			
TearLab Corporation 1.2 8,500 2,210			
• ==			
	• ==		
19,440,855			19,440,855
Health Care Providers & Services - 2.2%	Health Care Providers & Services - 2.2%		
AAC Holdings <u>1</u> 89,400 1,026,312		89,400	1,026,312
Aceto Corporation 79,600 604,960	Aceto Corporation	79,600	604,960

BioTelemetry 1/2 Cross Country Healthcare 1/2 National Research Cl. A Psychemedics Corporation 3/2 U.S. Physical Therapy	47,700 150,800 89,529 37,500 10,000	1,481,085 1,675,388 2,618,723 775,500 813,000
		8,994,968
Health Care Technology - 0.7% Connecture 1.2 Tabula Rasa HealthCare 1 Vocera Communications 1	20,000 50,000 33,100	7,000 1,940,000 775,202
		2,722,202
Life Sciences Tools & Services - 0.4% NeoGenomics 1 Quanterix Corporation 1	125,000 45,500	1,020,000 775,320
		1,795,320
Pharmaceuticals - 0.8% Agile Therapeutics 1.3.4 Corium International 1 Flex Pharma 1 Theravance Biopharma 1	80,000 4,900 328,620 59,009	205,600 56,203 1,643,100 1,430,968
		3,335,871
Total		55,873,353
Industrials 21.1% Aerospace & Defense - 0.5% Astronics Corporation 1 CPI Aerostructures 1 FLYHT Aerospace Solutions 1 Innovative Solutions and Support 1 Mercury Systems 1.3.4 SIFCO Industries 1	2,460 11,800 191,680 142,828 20,100 45,800	91,758 115,050 238,047 504,183 971,232 252,903
		2,173,173
Building Products - 1.3% Burnham Holdings Cl. A ² CSW Industrials ¹ DIRTT Environmental Solutions ¹ Insteel Industries Patrick Industries ¹	117,000 20,000 96,000 44,200 17,250	1,766,700 901,000 368,844 1,221,246 1,066,912
		5,324,702
Commercial Services & Supplies - 2.4% Atento Civeo Corporation 1 CompX International CI. A Heritage-Crystal Clean 1.3.4 Hudson Technologies 1 InnerWorkings 1	206,701 150,000 78,200 223,477 50,000 30,400	1,612,268 565,500 1,079,160 5,262,883 247,000 275,120

Team <u>1,3</u>	57,500	790,625
		9,832,556
Construction & Engineering - 2.7%	251 400	2 268 200
Ameresco Cl. A 1	251,400	3,268,200
IES Holdings 1 Infrastructure and Energy Alternatives 1	220,000 120,000	3,333,000 1,053,000
Layne Christensen 1.3.4	50,000	746,000
Northwest Pipe 1.3	61,600	1,065,680
NV5 Global 1,3	27,400	1,527,550
		10,993,430
Electrical Equipment - 0.9%		
Encore Wire 3	4,100	232,470
LSI Industries	147,412	1,195,511
Powell Industries	21,400	574,376
Power Solutions International 1,2,3,4	21,100	156,140
Preformed Line Products	20,743	1,350,162
Revolution Lighting Technologies 1.3.4	81,200	278,516
		3,787,175
Industrial Conglomerates - 0.9% Raven Industries 3	102,559	3,594,693
Machinery - 7.6%		
CIRCOR International 1,3	55,800	2,380,428
Eastern Company (The)	39,750	1,132,875
Exco Technologies	85,400	602,543
Foster (L.B.) Company ^{1,3,4}	95,300	2,244,315
FreightCar America 1	86,500	1,159,100
Global Brass and Copper Holdings	5,000	167,250
Graham Corporation 3,4	75,150	1,609,713
Harsco Corporation 1	4,400	90,860
Hurco Companies	36,866	1,692,149
Kadant	49,800	4,706,100
Kornit Digital 1	39,800	513,420
Lindsay Corporation 3	32,600	2,980,944
Luxfer Holdings 3	59,712	764,314
Lydall <u>1</u>	1,800	86,850
NN	45,300	1,087,200
Sun Hydraulics	74,000	3,963,440
Tennant Company	34,400	2,328,880
Titan International	212,200	2,675,842
Westport Fuel Systems 1	377,900	827,601
		31,013,824
Marine - 1.2%		
Clarkson	109,900	4,659,987
Professional Services - 1.5%	,	
Acacia Research 1,3	190,000	665,000
CBIZ 1	47,000	857,750
Franklin Covey 1	40,100	1,078,690
GP Strategies 1	7,600	172,140
Heidrick & Struggles International	46,300	1,446,875
IBI Group 1	84,500	475,511

Kforce $\frac{3}{2}$ Resources Connection RPX Corporation	2,800 11,200 96,000	75,740 181,440 1,026,240
		5,979,386
Road & Rail - 0.7% Marten Transport Patriot Transportation Holding 1,3	5,500 55,764	125,400 1,034,980
Universal Logistics Holdings 3	77,600	1,641,240 2,801,620
Trading Companies & Distributors - 1.4% Central Steel & Wire ²	788	370,368
EnviroStar ^{3,4} Houston Wire & Cable ¹	74,400 331,418	2,920,200 2,427,637
		5,718,205
Total		85,878,751
Information Technology 21.6% Communications Equipment - 0.6%		
ADTRAN 3	23,300	362,315
Clearfield 1	61,300	790,770
EMCORE Corporation 1	8,300	47,310
Harmonic 1	147,000	558,600
Oclaro 1 PCTEL	32,600 34,100	311,656 244,838
		2,315,489
Electronic Equipment, Instruments & Components - 7.4%		
Airgain 1,3	8,200	63,468
Bel Fuse Cl. A	67,705	1,117,132
eMagin Corporation 1 eMagin Corporation (Warrants) 1.5	125,000 50,000	181,250 0
ePlus 1	3,000	233,100
Fabrinet 1	2,200	69,036
FARO Technologies 1,3,4	76,800	4,485,120
Firan Technology Group 1	25,000	57,244
HollySys Automation Technologies Inficon Holding	51,900 3,220	1,282,968 1,980,999
LightPath Technologies Cl. A 1	50,000	110,000
Littelfuse	1,264	263,139
LRAD Corporation 1	853,456	1,962,949
Mesa Laboratories ³	45,400	6,739,176
Novanta 1 Orbotech 1.3.4	37,600 87,000	1,960,840 5,409,660
PC Connection	43,716	1,092,900
Perceptron 1	8,500	72,675
Richardson Electronics	316,900	2,519,355
Rogers Corporation 1.3 Vishay Precision Group 1	600 10,000	71,724 311,500
, , ,	,	29,984,235

Internet Software & Services - 4.9%

Amber Road 1 Care.com 1.3.4 comScore 1.2 Etsy 1.3 IZEA 1.3.4 Leaf Group 1 MINDBODY CI. A 1 QuinStreet 1 Real Matters 1 Reis 3 Solium Capital 1 Stamps.com 1 Support.com 1	25,000 171,787 64,195 80,300 85,870 64,500 38,900 264,550 255,000 25,000 317,500 12,300 105,600	222,500 2,794,974 1,534,261 2,253,218 314,284 454,725 1,513,210 3,378,304 1,442,892 536,250 2,752,726 2,472,915 291,456
IT Services - 0.6% Computer Task Group 1.3 Conduent 1 Hackett Group (The) Innodata 1	150,838 30,000 27,700 354,275	1,235,363 559,200 444,862 382,617 2,622,042
Semiconductors & Semiconductor Equipment - 4.9% Alpha & Omega Semiconductor 1 Amtech Systems 1.3 Brooks Automation CyberOptics Corporation 1 Everspin Technologies 1 FormFactor 1 Intermolecular 1 Kopin Corporation 1 Kulicke & Soffa Industries 1 Nanometrics 1 NeoPhotonics Corporation 1.3 Nova Measuring Instruments 1 PDF Solutions 1 Photronics 1 Rudolph Technologies 1 Silicon Motion Technology ADR Ultra Clean Holdings 1.3 Veeco Instruments 1.3 Xcerra Corporation 1	3,300 92,184 91,500 43,000 5,900 22,869 240,000 242,200 77,200 64,600 51,300 68,000 189,700 231,900 52,100 34,100 49,900 17,500 15,600	50,985 674,787 2,477,820 774,000 44,545 312,162 314,400 755,664 1,930,772 1,737,740 351,405 1,844,840 2,211,902 1,913,175 1,443,170 1,640,892 960,575 297,500 181,740
Software - 2.1% Agilysys ½ American Software Cl. A BSQUARE Corporation ½ Computer Modelling Group Monotype Imaging Holdings PSI Software RealNetworks ½ Redknee Solutions ½ Rubicon Project ½ SeaChange International ½ Varonis Systems ½	170,587 120,352 83,675 337,700 15,000 23,000 100,171 150,000 75,000 284,200 2,600	2,033,397 1,564,576 355,619 2,435,078 336,750 488,287 306,523 122,250 135,000 770,182 157,300

		8,704,962
Technology Hardware, Storage & Peripherals - 1.1%		
AstroNova Cray 1	5,300 19,700	82,150 407,790
Intevac 1	301,800	2,082,420
Kortek	135,007	1,785,113
USA Technologies 1	12,300	110,700
		4,468,173
Total		87,974,690
Materials 5.7%		
Chemicals - 2.2%		
Balchem Corporation	11,775	962,606
FutureFuel Corporation LSB Industries 1	85,262 135,800	1,022,292 832,454
OMNOVA Solutions 1	25,000	262,500
Quaker Chemical 3	24,400	3,614,372
Rayonier Advanced Materials	50,000	1,073,500
Trecora Resources 1	89,600	1,218,560
		8,986,284
Construction Materials - 0.3%		
Monarch Cement ²	16,303	1,219,464
U.S. Concrete 1	2,500	151,000
		1,370,464
Containers & Packaging - 0.3%		
UFP Technologies 1	36,445	1,075,127
Metals & Mining - 2.9%		
Alamos Gold Cl. A	186,044	967,513
Ampco-Pittsburgh 1	79,002	703,118
Haynes International 3	27,400	1,016,814
Hudbay Minerals	62,200	441,620
Imdex 1	750,666	687,387
MAG Silver 1 Major Drilling Group International 1	154,050 921,657	1,501,987 4,764,416
Olympic Steel	35,000	717,850
Pretium Resources 1	80,000	531,533
Universal Stainless & Alloy Products 1	15,300	420,750
Victoria Gold 1	890,000	248,690
		12,001,678
Total		23,433,553
P. (15.1)		
Real Estate 4.2% Equity Real Estate Investment Trusts (REITs) - 0.3%		
BRT Apartments	101,331	1,190,639
Real Estate Management & Development - 3.9%		
Altus Group	87,000	2,202,771

Edgar Filing: ROYCE MICRO-CAP TRUST,	, IING FC	א-מוווונ
--------------------------------------	-----------	----------

	· · · · · · · · · · · · · · · · · · ·	
FRP Holdings 1,3,4	76,500	4,284,000
Griffin Industrial Realty	34,784	1,305,444
Hopefluent Group Holdings	400,000	192,679
Marcus & Millichap 1,3	49,567	1,787,386
RMR Group Cl. A	34,900	2,441,255
Tejon Ranch 1,3	154,994	3,581,911
rejon nanon	104,004	3,301,311
		15 705 446
		15,795,446
Tatal		10,000,000
Total		16,986,085
Talaaannaniaatian Oomiaaa 000/		
Telecommunication Services 0.2%		
Diversified Telecommunication Services - 0.2%	07.400	000 707
ORBCOMM 1	67,100	628,727
Total		628,727
Utilities 0.5%		
Gas Utilities - 0.1%		
Shizuoka Gas	40,000	361,789
Independent Power & Renewable Electricity Producer - 0.0%		
Innergex Renewable Energy	15,573	159,193
minorgox nonewable Energy	10,070	100,100
Water Hillities 0.49/		
Water Utilities - 0.4%	F0 000	004 000
AquaVenture Holdings 1	50,000	621,000
Global Water Resources	106,000	950,820
		1,571,820
Total		2,092,802
TOTAL COMMON STOCKS		
(Cost \$344,745,427)		423,379,841
REPURCHASE AGREEMENT 7.6%		
Fixed Income Clearing Corporation,		
0.28% dated 3/29/18, due 4/2/18,		
maturity value \$31,258,972 (collateralized		
by obligations of various U.S. Government		
Agencies, 0.125% due 7/15/22, valued at \$31,888,347)		
(Cost \$31,258,000)		31,258,000
(333. 401,200,000)		01,200,000
TOTAL INVESTMENTS 111.4%		
(Cost \$376,003,427)		454,637,841
(ΟΟΟ: ΨΟΙΟ,ΟΟΟ,ΤΖΙ)		TUT,UU1,UH1
LIABILITIES LESS CASH		
AND OTHER ASSETS (11.4)%		(46,613,702)
· · · · · · · · · · · · · · · · · · ·		(13,013,702)
NET ASSETS 100.0%		\$408,024,139
		ψ .00,0±1,100

¹ Non-income producing.

- ² These securities are defined as Level 2 securities due to fair value being based on quoted prices for similar securities.
- ³ All or a portion of these securities were pledged as collateral in connection with the Fund s revolving credit agreement at March 31, 2018. Total market value of pledged securities at March 31, 2018, was \$75,622,216.
- ⁴ At March 31, 2018, a portion of these securities were rehypothecated in connection with the Fund s revolving credit agreement in the aggregate amount of \$39,295,568.
- ⁵ Securities for which market quotations are not readily available represent 0.1% of net assets. These securities have been valued at their fair value under procedures approved by the Fund s Board of Directors. These securities are defined as Level 3 securities due to the use of significant unobservable inputs in the determination of fair value.

TAX INFORMATION: The cost of total investments for Federal income tax purposes was \$377,407,735. At March 31, 2018, net unrealized appreciation for all securities was \$77,230,106, consisting of aggregate gross unrealized appreciation of \$127,070,132 and aggregate gross unrealized depreciation of \$49,840,026. The primary cause of the difference between book and tax basis cost is the timing of the recognition of losses on securities sold.

Valuation of Investments:

Investment transactions are accounted for on the trade date. Securities are valued as of the close of trading on the New York Stock Exchange (NYSE) (generally 4:00 p.m. Eastern time) on the valuation date. Securities that trade on an exchange, and securities traded on Nasdag s Electronic Bulletin Board, are valued at their last reported sales price or Nasdag official closing price taken from the primary market in which each security trades or, if no sale is reported for such day, at their highest bid price. Other over-the-counter securities for which market quotations are readily available are valued at their highest bid price, except in the case of some bonds and other fixed income securities which may be valued by reference to other securities with comparable ratings, interest rates and maturities, using established independent pricing services. The Fund values its non-U.S. dollar denominated securities in U.S. dollars daily at the prevailing foreign currency exchange rates as quoted by a major bank. Securities for which market quotations are not readily available are valued at their fair value in accordance with the provisions of the 1940 Act, under procedures approved by the Fund s Board of Directors, and are reported as Level 3 securities. As a general principle, the fair value of a security is the amount which the Fund might reasonably expect to receive for the security upon its current sale. However, in light of the judgment involved in fair valuations, there can be no assurance that a fair value assigned to a particular security will be the amount which the Fund might be able to receive upon its current sale. In addition, if, between the time trading ends on a particular security and the close of the customary trading session on the NYSE, events occur that are significant and may make the closing price unreliable, the Fund may fair value the security. The Fund uses an independent pricing service to provide fair value estimates for relevant non-U.S. equity securities on days when the U.S. market volatility exceeds a certain threshold. This pricing service uses proprietary correlations it has developed between the movement of prices of non-U.S. equity securities and indices of U.S.-traded securities, futures contracts and other indications to estimate the fair value of relevant non-U.S. securities. When fair value pricing is employed, the prices of securities used by the Fund may differ from guoted or published prices for the same security. Investments in money market funds are valued at net asset value per share.

Various inputs are used in determining the value of the Fund s investments, as noted above. These inputs are summarized in the three broad levels below:

- Level 1 quoted prices in active markets for identical securities.
- other significant observable inputs (including quoted prices for similar securities, foreign securities that may be fair valued Level 2 and repurchase agreements). The table below includes all Level 2 securities. Level 2 securities with values based on quoted prices for similar securities are noted in the Schedule of Investments.
- significant unobservable inputs (including last trade price before trading was suspended, or at a discount thereto for lack Level 3 of marketability or otherwise, market price information regarding other securities, information received from the company and/or published documents, including SEC filings and financial statements, or other publicly available information).

The inputs or methodology used for valuing securities are not necessarily an indication of the risk associated with investing in those securities.

The following is a summary of the inputs used to value the Fund s investments as of March 31, 2018. For a detailed breakout of common stocks by sector classification, please refer to the Schedule of Investments.

	Level 1	Level 2	Level 3	Total
Common Stocks	\$394,882,286	\$28,255,755	\$241,800	\$423,379,841
Cash Equivalents		31,258,000		31,258,000

Certain securities have transferred in and out of Level 1 and Level 2 measurements during the reporting period. The Fund recognizes transfers between levels as of the end of the reporting period. For the three months ended March 31, 2018, securities valued at \$1,333,278 were transferred from Level 1 to Level 2 within the fair value hierarchy.

Level 3 Reconciliation:

Balance as of		Realized	Unrealized	
12/31/17	Purchases	Gain (Loss)	Gain (Loss)	Balance as of 3/31/18

Common Stocks \$241,800 \$0 \$ \$ \$241,800

The following table summarizes the valuation techniques used and unobservable inputs approved by the Valuation Committee to determine the fair value of certain Level 3 investments. The table does not include Level 3 investments with values derived utilizing prices from prior transactions or third party pricing information with adjustments (e.g. broker quotes, pricing services, net asset values).

	Fair Value at 3/31/18	Valuation Technique(s)	Unobservable Input(s)	Range Average	Impact to Valuation From an Increase in Input1
Common Stocks	\$241,800	Discounted Present Value Balance Sheet Analysis	Liquidity Discount	30%-40%	Decrease

¹ This column represents the directional change in the fair value of the Level 3 investments that would result in an increase from the corresponding unobservable input. A decrease to the unobservable input would have the opposite effect. Significant increases and decreases in these unobservable inputs in isolation could result in significantly higher or lower fair value measurements.

Repurchase Agreements:

The Fund may enter into repurchase agreements with institutions that the Fund s investment adviser has determined are creditworthy. The Fund restricts repurchase agreements to maturities of no more than seven days. Securities pledged as collateral for repurchase agreements, which are held until maturity of the repurchase agreements, are marked-to-market daily and maintained at a value at least equal to the principal amount of the repurchase agreement (including accrued interest). Repurchase agreements could involve certain risks in the event of default or insolvency of the counter-party, including possible delays or restrictions upon the ability of the Fund to dispose of its underlying securities. The remaining contractual maturity of the repurchase agreement held by the Fund at March 31, 2018 is overnight and continuous.

Borrowings:

The Fund is party to a revolving credit agreement (the credit agreement) with BNP Paribas Prime Brokerage International, Limited (BNPPI). As of March 31, 2018, the Fund has outstanding borrowings of \$45,000,000. During the period ended March 31, 2018, the Fund borrowed an average daily balance of \$45,000,000. The Fund pays a commitment fee of 0.50% per annum on the unused portion of the credit agreement. The credit agreement has a 360-day rolling term that resets daily; however, if the Fund exceeds certain net asset value triggers, the credit agreement may convert to a 60-day rolling term that resets daily. The Fund is required to pledge portfolio securities as collateral in an amount up to two times the loan balance outstanding or as otherwise required by applicable regulatory standards and has granted a security interest in the securities pledged to, and in favor of, BNPPI as security for the loan balance outstanding. If the Fund fails to meet certain requirements, or maintain other financial covenants required under the credit agreement, the Fund may be required to repay immediately, in part or in full, the loan balance outstanding under the credit agreement which may necessitate the sale of portfolio securities at potentially inopportune times. BNPPI may terminate the credit agreement upon certain ratings downgrades of its corporate parent, which would result in the Fund s entire loan balance becoming immediately due and payable. The occurrence of such ratings downgrades may necessitate the sale of portfolio securities at potentially inopportune times. The credit agreement also permits, subject to certain conditions, BNPPI to rehypothecate portfolio securities pledged by the Fund up to the amount of the loan balance outstanding. The Fund continues to receive payments in lieu of dividends and interest on rehypothecated securities. The Fund also has the right under the credit agreement to recall the rehypothecated securities from BNPPI on demand. If BNPPI fails to deliver the recalled security in a timely manner, the Fund is compensated by BNPPI for any fees or losses related to the failed delivery or, in the event a recalled security is not returned by BNPPI, the Fund, upon notice to BNPPI, may reduce the loan balance outstanding by the value of the recalled security failed to be returned. The Fund receives a portion of the fees earned by BNPPI in connection with the rehypothecation of portfolio securities.

Other information regarding the Fund is available in the Fund s most recent Report to Stockholders. This information is available through The Royce Funds (www.roycefunds.com) and on the Securities and Exchange Commission s website (www.sec.gov).

Item 2 - Controls and Procedures

(a) The Registrant's principal executive and principal financial officers have concluded, based on their evaluation of the Registrant's disclosure controls and procedures as of a date within 90 days of the filing date of this report (as required by Rule 30a-3(b) under the Investment Company Act of 1940 (the "Act")), that the Registrant's disclosure controls and procedures (as defined by Rule 30a-3(c) under the Act) are reasonably designed to ensure that information required to be disclosed by the Registrant on Form N-Q is recorded, processed, summarized and reported within the required time periods and that information required to be disclosed by the Registrant in the reports that it files or submits on Form N-Q is accumulated and communicated to the Registrant's management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure.

(b) There were no changes in the Registrant's internal control over financial reporting (as defined in Rule 30a-3(d) under the Act) during the Registrant's last fiscal quarter that have materially affected, or are reasonably likely to materially affect, the internal control over financial reporting.

Item 3 - Exhibits

Certifications pursuant to Rule 30a-2(a) under the Act are attached hereto.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934 and the Investment Company Act of 1940, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Royce Micro-Cap Trust, Inc.

By:

/s/ Christopher D. Clark

Christopher D. Clark

President, Royce Micro-Cap Trust, Inc.

Date: May 29, 2018

Pursuant to the requirements of the Securities Exchange Act of 1934 and the Investment Company Act of 1940, this
report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the
dates indicated.

dates indicated.
By:
/s/ Christopher D. Clark
Christopher D. Clark
President, Royce Micro-Cap Trust, Inc.
Date: May 29, 2018
By:

/s/ Peter K. Hoglund

Peter K. Hoglund

Treasurer, Royce Micro-Cap Trust, Inc.

Date: May 29, 2018